B019 injection for relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational cell therapy called B019 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to treatment. The therapy targets cancer cells that have CD19 and/or CD22 on their surface, and the study aims to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with B-cell non-Hodgkin's lymphoma that has returned or not responded to previous treatment.
- Your cancer cells test positive for CD19 and/or CD22 markers.
- You are well enough to carry out daily activities (ECOG score 0–2) and expect to live at least 12 more weeks.
- You have at least one measurable tumor on a scan.
- You have not had a stem cell transplant from another person in the past, and don't have certain serious heart, brain, or immune system conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests an experimental cell therapy (RJMty19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hear when a new Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.